Evidence map›Paper›PMID 40573952›Full record

ReviewVaccines2025

Vaccination Strategies and Research Gaps in Hepatitis E Virus for Special Populations.

Meng Wang, Binwei Duan, Mengcheng Liu, Yuxuan Zhang, Feng Wu, Guangming Li, Yabo Ouyang

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Vaccines, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Meng WangDepartment of General Surgery Center, Beijing YouAn Hospital, Capital Medical University, Beijing Institute of Hepatology, Beijing 100069, China.
Binwei DuanDepartment of General Surgery Center, Beijing YouAn Hospital, Capital Medical University, Beijing Institute of Hepatology, Beijing 100069, China.
Mengcheng LiuDepartment of General Surgery Center, Beijing YouAn Hospital, Capital Medical University, Beijing Institute of Hepatology, Beijing 100069, China.
Yuxuan ZhangDepartment of General Surgery Center, Beijing YouAn Hospital, Capital Medical University, Beijing Institute of Hepatology, Beijing 100069, China.
Feng WuDepartment of General Surgery Center, Beijing YouAn Hospital, Capital Medical University, Beijing Institute of Hepatology, Beijing 100069, China.
Guangming LiDepartment of General Surgery Center, Beijing YouAn Hospital, Capital Medical University, Beijing Institute of Hepatology, Beijing 100069, China.ORCID 0000-0002-3311-1108
Yabo OuyangDepartment of General Surgery Center, Beijing YouAn Hospital, Capital Medical University, Beijing Institute of Hepatology, Beijing 100069, China.ORCID 0009-0003-0349-5213

Funding

Beijing Hospitals Authority Youth Programme QML20201701Beijing Municipal Health Commission of Beijing Municipal Public Welfare Development and Reform Pilot Project for Medical Research Institutes JYY2021-10Beijing Natural Science Foundation L244033, L222067, L202024, M21006Capital's Funds for Health Improvement and Research 2024-2-1153Key medical professional development plan of Beijing Hospital Authority ZYLX202124National Science and Technology Major Projects 2023ZD0502405
6 · The paper itself

Abstract

backgroundHepatitis E virus (HEV) infection poses a significant health risk across diverse demographic groups, particularly among pregnant women, immunocompromised individuals, patients with chronic liver disease, and the elderly. The global epidemiology of HEV reveals distinct patterns of prevalence, transmission, and disease severity among these populations, necessitating targeted vaccination strategies. The licensing of the Hecolin (HEV 239) vaccine offers promise, but gaps in clinical trial data and varying immune responses in high-risk groups challenge its widespread applicability. SCOPE: This review synthesizes data on HEV's epidemiology, discusses the susceptibility of vulnerable populations, evaluates the efficacy and safety of HEV 239, and highlights the urgent need for clinical research tailored to these groups. Key findings underscore the complexity of vaccine response influenced by immunological, physiological, and environmental factors. Additionally, potential advancements in vaccine technology, including the development of broad-spectrum vaccines and innovative delivery systems, are discussed as future directions. STRATEGIES: Addressing regulatory, economic, and logistical barriers remains crucial for effective HEV vaccination programs. A multidisciplinary approach integrating public health policy, rigorous clinical evaluations, and collaborative frameworks is essential to ensure equitable access to HEV vaccination, ultimately improving health outcomes on a global scale.

Indexed as

chronic liver diseaseHepatitis E virusHEV epidemiologyimmunocompromised individualspregnant womenspecial populationsthe elderlyvaccination strategies

Identifiers

PMID40573952
PMCPMC12197322

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.